Holen Sie sich die Stockscreener-App
22.75
9.65%
-2.43
Handel nachbörslich:
22.80
0.05
+0.22%
Schlusskurs vom Vortag:
$25.18
Offen:
$25.39
24-Stunden-Volumen:
1.11M
Relative Volume:
1.09
Marktkapitalisierung:
$2.81B
Einnahmen:
Nettoeinkommen (Verlust:
KGV:
-
EPS:
-
Netto-Cashflow:
1W Leistung:
-17.21%
1M Leistung:
-38.31%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$22.66
$25.70
1-Wochen-Bereich:
$22.66
$29.50
52-Wochen-Spanne:
$22.66
$42.48
Parabilis Medicines Inc Stock (PBLS) Company Profile
Firmenname
Parabilis Medicines Inc
Sektor
Branche
Telefon
-
Adresse
-
Compare PBLS vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PBLS
Parabilis Medicines Inc
|
22.75 | 2.81B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Parabilis Medicines Inc Stock (PBLS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-07-06 | Eingeleitet | BofA Securities | Buy |
| 2026-07-06 | Eingeleitet | Evercore ISI | Outperform |
| 2026-07-06 | Eingeleitet | Guggenheim | Buy |
| 2026-07-06 | Eingeleitet | Leerink Partners | Outperform |
Parabilis Medicines Inc Aktie (PBLS) Neueste Nachrichten
Parabilis Medicines, Inc. (PBLS) Stock Price, News, Quote & History - Yahoo! Finance Canada
PBLS Price Today: Parabilis Medicines, Inc. Stock Price, Quote & Chart | MEXC - MEXC
Parabilis Medicines (Nasdaq:PBLS)Stock Analysis - Simply Wall Street
48,484 Shares in Parabilis Medicines, Inc. $PBLS Acquired by Squarepoint Ops LLC - marketbeat.com
Parabilis Medicines (PBLS) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
1,920,805 Shares in Parabilis Medicines, Inc. $PBLS Purchased by Frazier Life Sciences Management L.P. - MarketBeat
Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference - Yahoo Finance
ICONIQ Capital LLC Takes $9.58 Million Position in Parabilis Medicines, Inc. $PBLS - MarketBeat
Regeneron Pharmaceuticals Inc. Buys New Stake in Parabilis Medicines, Inc. $PBLS - marketbeat.com
Parabilis Medicines, Inc. (PBLS) Stock Price & News - Syfe
1,600,937 Shares in Parabilis Medicines, Inc. $PBLS Purchased by General Catalyst Group Management LLC - MarketBeat
venBio Partners LLC Takes $144.15 Million Position in Parabilis Medicines, Inc. $PBLS - MarketBeat
Jupiter Topco LLC Buys Shares of 2,296,547 Parabilis Medicines, Inc. $PBLS - MarketBeat
Parabilis Medicines, Inc. (NASDAQ:PBLS) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Parabilis appoints Craig Tendler to its Board and Science & Technology Committee - TradingView
Parabilis Medicines adds former J&J oncology executive to board By Investing.com - Investing.com Canada
Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors - Yahoo Finance
ICONIQ Capital LLC Makes New Investment in Parabilis Medicines, Inc. $PBLS - MarketBeat
Parabilis Medicines Price Insights - YCharts
Parabilis Medicines (NASDAQ:PBLS) Stock Price Up 5.9%Here's What Happened - MarketBeat
Alphabet Inc. Makes New $134.65 Million Investment in Parabilis Medicines, Inc. $PBLS - MarketBeat
Biotech’s reverse merger renaissance poised to continue - Endpoints News
Parabilis Medicines (NASDAQ:PBLS) Sets New 1-Year HighWhat's Next? - MarketBeat
Focus Partners Advisor Solutions LLC Invests $1.35 Million in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Celcuity (CELC) and Parabilis Medicines, Inc. (PBLS) - The Globe and Mail
Parabilis Medicines(PBLS) Stock Options Chain | Quotes & News - Moomoo
Parabilis Medicines(PBLS) Stock Options Chain | Quotes & News - Moomoo
Parabilis Medicines (PBLS): ARCH Venture group discloses 6.4M-share, 5.3% ownership - Stock Titan
BofA Securities Maintains Parabilis Medicines(PBLS.US) With Buy Rating - Moomoo
Parabilis Medicines: A Rare-Tumor Validation Ladder For An Undruggable Platform (NASDAQ:PBLS) - Seeking Alpha
Parabilis Medicines, Inc. Common Stock (NASDAQ: PBLS) Stock Price, News & Analysis - kalkine.ca
Parabilis Medicines, Inc. Common Stock (NASDAQ: PBLS) Stock Price, News & Analysis - kalkine.com.au
PBLS SWOT Analysis: Financial Resilience Amidst Clinical Challen - GuruFocus
Parabilis Medicines (PBLS) Earnings Date and Reports 2026 - MarketBeat
Parabilis Medicines (PBLS) boosts cash above $1.1B after IPO and Regeneron deal - Stock Titan
Form 8K Parabilis Medicines For: 13 August By Investing.com - Investing.com Nigeria
PBLS: Lead asset zolucatetide shows strong efficacy and safety, driving a robust pipeline and growth - TradingView
Form 8K Parabilis Medicines For: 13 August By Investing.com - Investing.com South Africa
Parabilis Medicines Q2 Loss Narrows; Shares Rise Pre-Bell - marketscreener.com
Earnings Flash (PBLS) Parabilis Medicines Posts Q2 Net Loss $2.32 a Share - marketscreener.com
Form 8K Parabilis Medicines For: 13 August By Investing.com - Investing.com Canada
Form 8K Parabilis Medicines For: 13 August By Investing.com - Investing.com Australia
Form 8K Parabilis Medicines For: 13 August By Investing.com - Investing.com India
Parabilis Medicines Reports Second Quarter 2026 Financial Results And Provides Business Updates - TradingView
Form 8K Parabilis Medicines For: 13 August By Investing.com - Investing.com UK
Earnings Flash (PBLS) Parabilis Medicines, Inc. Reports Q2 Revenue $148,000 - marketscreener.com
Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Parabilis Medicines Advances Zolucatetide Toward Phase 3 in Desmoid Tumors, Announces Regeneron Collaboration and $1.1 Billion Cash Position - Quiver Quantitative
Parabilis Medicines: Q2 Earnings Snapshot - marketscreener.com
Parabilis Medicines: Q2 Earnings Snapshot - AOL.com
Finanzdaten der Parabilis Medicines Inc-Aktie (PBLS)
Es liegen keine Finanzdaten für Parabilis Medicines Inc (PBLS) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Parabilis Medicines Inc-Aktie (PBLS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Director |
Jul 22 '26 |
Buy |
29.77 |
47,250 |
1,406,632 |
26,529,686 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Jul 21 '26 |
Buy |
29.25 |
65,923 |
1,928,032 |
26,482,436 |
| SEBULSKY ALAN | Director |
Jun 15 '26 |
Buy |
26.49 |
9,065 |
240,135 |
30,000 |
| SEBULSKY ALAN | Director |
Jun 12 '26 |
Buy |
27.67 |
8,435 |
233,393 |
20,935 |
| Levy Guy | 10% Owner |
Jun 11 '26 |
Buy |
20.00 |
500,000 |
10,000,000 |
1,027,000 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Jun 11 '26 |
Buy |
20.00 |
21,188,750 |
423,775,000 |
26,285,093 |
| SEBULSKY ALAN | Director |
Jun 11 '26 |
Buy |
20.00 |
12,500 |
250,000 |
12,500 |
3.98%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):